INOVIO (NASDAQ:INO),a biotechnology company focused on developing and commercializing DNA medicines tohelp treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has madean equity grant toa newly hired employeeunder its 2022 Inducement Plan (the “Inducement Plan”).
https://mma.prnewswire.com/media/2310866/INOVIO_v1_Logo.jpg
The Compensation Committee of INOVIO's Board of Directors has approvedtheaward of an option to purchase 1,302shares of common stock with a grant date of September30, 2025(the “Grant Date”), to anewlyhired employee in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $2.34, the closing price of INOVIO's common stock on September 30, 2025. The stock option will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreementunder the Inducement Plan.
About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
ContactsMedia: Jennie Willson, (267) 429-8567, communications@inovio.comInvestors: PeterVozzo – ICR Healthcare, 443-213-0505,investor.relations@inovio.com
https://edge.prnewswire.com/c/img/favicon.png?sn=PH88985&sd=2025-10-02
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302573337.html
SOURCE INOVIO Pharmaceuticals, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=PH88985&Transmission_Id=202510020805PR_NEWS_USPR_____PH88985&DateId=20251002